< back to all PPMI Presentations

Relationship between Serum Urate and Clinical Features in Early Parkinsons Disease: PPMI Baseline Data

Constantinescu, R; Jennings, D; Foster, E.D; Auinger, P; Coffey, C.S; Marerk, K; the Parkinson\'s Progression Marker Initiative
MDS: Sydney, Australia
Download Presentation: Urate-MDS poster June 10-2013.pdf
To investigate serum urate (S-urate) levels and their relationship with clinical features at baseline in the early Parkinson's disease (PD) and healthy control (HC) cohort enrolled in the Parkinson Progression Marker Initiative (PPMI) study.
Previous studies found higher S-urate levels to be associated with a lower risk for developing PD [1] and with a slower rate of disease progression in PD.
Cross-sectional sub-analysis of PPMI baseline data for the first 507 enrolled subjects (PD=343 [224 M, 119 F], HC=164 [100 M, 64 F]). S-urate was measured by a commercial laboratory (Covance). Cerebrospinal fluid (CSF) a-synuclein was analyzed using a commercially available ELISA. Clinical features were assessed per PPMI protocol. Two sample t-tests were used to assess the difference in mean S-urate between PD and HC subjects, adjusting for gender. Within PD subjects, the association of S-urate with other biomarkers and clinical variables was investigated using univariate linear regressions and correlations.
S-urate levels were not significantly different in PD (M 350.2+72.5, F 258.7±54.0) compared with HC subjects (M 343.7±63.7, F 270.5±50.3). In PD, there were no significant correlations between S-urate levels and clinical features, assessed using The Movement Disorder Society UPDRS part III, the Montreal Cognitive Assessment, and the Geriatric Depression Scale, or with CSF a-synuclein levels.
According to these preliminary results using this simplified means analysis, there was no significant difference in baseline S-urate levels in PD subjects compared with HC. Baseline S-urate levels were not associated with various clinical features at early PD stages in the PPMI population. Additional, more detailed analyses are underway. [1] Davis JW, Grandinetti A, Waslien CI, Ross GW, White LR, Morens DM. Observations on serum uric acid levels and the risk of idiopathic Parkinson's disease. American journal of epidemiology. 1996;144:480-4.